Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

GNLX

Phase 3

Olvi-Vec (Olvimulogene nanivacirepvec) + platinum-doublet + bevacizumab

Platinum-resistant or refractory ovarian cancer

H2 2025

OnPrime/GOG-3076 trial. 09/2022- Initiated trial. Trial ongoing. 11/27/23- Granted Fast Track Designation. 4/1/24- Topline data in H2 2025.

Data readout

EWTX

Phase 2

EDG-7500

Hypertrophic cardiomyopathy (HCM)

H2 2025

CIRRUS-HCM trial. 3/28/24- Presentation at ACC '24 on April 7th. 5/6/24- First patient dosed in Ph2 trial. 9/19/24- Reported Ph1 topline data and Ph2 single-dose arm. 3/3/25- Report 12wk data in H2 2025.

Data Readout

NTLA

Phase 1/2

NTLA-2002 (KLKB1 Inhibitor)

Type I or II HAE (Hereditary Angioedema)

2025

HAELO study. 10/24/24- Reported Ph2 results. 1/10/25- Dose first patient in Q1 2025 and complete enrollment in H2 2025 (Ph3 HAELO study). Present long-term Ph1/2 data in 2025. Submit BLA in H2 2026. 1/22/25- First patient dosed in Ph3 study.

Data readout

BEAM

Phase 1/2

BEAM-302

Alpha-1 antitrypsin deficiency

H2 2025

3/26/24- CTA cleared. 5/7/24- Initiate trial in H1 2024. 6/26/24 - First patient dosed. 3/10/25- Reported initial data. Updated data from Part A to be presented at a medical conference in H2 2025.

Data readout

BLTE

Phase 3

Tinlarebant (LBS-008)

Stargardt disease (STGD1)

Q4 2025

LBS-008-CT02/DRAGON studies. 5/1/24- Ph3 DRAGON study enrollment complete. 2/27/25- DSMB recommended trial proceed without any modifications following interim analysis. Trial completion by Q4 2025.

Data readout

ROIV

Phase 3

Brepocitinib

Dermatomyositis (DM)

H2 2025

VALOR: Enrollment complete, Ph3 Topline results in H2 2025.

Data Readout

ACIU

Phase 1b/2

ACI-24.060 (anti-Abeta vaccine)

Prodromal Alzheimer's Disease (AD) and in adults with Down Syndrome (DS)

H2 2025

ABATE study. 1/3/24- Completed enrollment of cohorts 1 & 2. 12/10/24- Interim safety data reported. 3/13/25- Interim data in H2 2025.

Data readout

KRRO

Phase 1/2

KRRO-110

Alpha-1 Antitrypsin Deficiency (AATD)

H2 2025

REWRITE trial. 11/21/24- AU HREC Approval & CTN clearance to initiate Ph1/2a with first participant dosing in Q1 2025. Interim data in H2 2025 and trial completion in 2026. 1/13/25- First patient dosed in Ph1/2a. 3/14/25- Receives Orphan Drug Designation.

Data readout

CALT

Phase 2

Setanaxib (NOX1/NOX4 inhibitor)

Alport syndrome

2025

9/27/23- Initiate trial w/ around 20 patients in Q4 2023. 10/5/23- EMA COMP issued positive opinion on orphan drug designation. 11/30/23- Trial initiated. 7/26/24- Topline data in 2025.

Data readout

GLPG

Phase 3

Filgotinib

axial spondyloarthritis (AxSpA)

H2 2025

OLINGUITO study. Topline results in H2 2025.

Data Readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20